Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2024-04-12 00:00:00 ET · period of report 2024-01-01 · accession 0000897069-24-000925 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-12 | 2024-01-01 | PCSA | Young David | Pres. Research, Development, Dir | F - Tax | $2.79 | -518 | 80.5K | -0.6% | -$1,445 |
| D | 2024-04-12 | 2024-01-01 | PCSA | Young David | Pres. Research, Development, Dir | M - OptEx | — | +1,675 | 81.1K | +2% | — |
| D | 2024-04-12 | 2024-01-01 | PCSA | Young David | Pres. Research, Development, Dir | M - OptEx | $0.00 | -1,675 | 19.3K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-01 | F | D | 518 | $2.79 | 80,544 | D | — | — | (F2) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. |
| 2 | Common | Common Stock | 2024-01-01 | M | A | 1,675 | — | 81,062 | D | — | — | (F1) Distribution of vested restricted shares. (F2) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. |
| 3 | Derivative | Restricted Stock Units | 2024-01-01 | M | D | 1,675 | $0.00 | 19,333 | D | $0.00 · — to — | 1,675 Common Stock | (F2) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. (F1) Distribution of vested restricted shares. |